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Abstract
The silicone elastomer solubilities of a range of drugs and pharmaceutical excipients employed in the development of silicone
intravaginal drug delivery rings (polyethylene glycols, norethisterone acetate, estradiol, triclosan, oleyl alcohol, oxybutynin) have
been determined using dynamic mechanical analysis. The method involves measuring the concentration-dependent decrease in the
storage modulus associated with the melting of the incorporated drug/excipient, and extrapolation to zero change in storage
modulus. The study also demonstrates the effect of drug/excipient concentrations on the mechanical stiffness of the silicone devices
at 371C. r 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Silicone intravaginal rings (IVRs) are elastomeric,
torus-shaped drug delivery devices (Fig. 1) designed to
release drug(s) to the vagina [1–3]. The rings have, to
date, been primarily developed for the systemic delivery
of contraceptive steroids [1,4–7] and the localized and
systemic delivery of steroids for hormone replacement
therapy [1–3,8–10], although it is likely they will in the
future be exploited for a much wider range of
applications within women’s health care including the
delivery of anti-infective agents and HIV microbicides.
Unsurprisingly, the IVR, which was specifically designed
for the intravaginal administration of drugs, overcomes
many of the disadvantages associated with more
traditional vaginal drug dosage forms, such as gels,
tablets and pessaries, which are often difﬁcult to apply,
interfere with intercourse and are poorly retained within
the vagina [1]. However, the major advantage of the
IVR is its ability and versatility in providing long-term,
continuous release of drug(s) at constant pre-determined
rates, thereby increasing cost-effectiveness, patient
compliance and therapeutic efﬁcacy [1].
Several designs of IVR have been developed, includ-
ing matrix, reservoir and shell-type variants, each
providing very different drug release proﬁles [1,4,11].
As with all diffusion/permeation-controlled delivery
systems, the two major parameters inﬂuencing drug
release rates from IVRs are the solubility and diffusivity
of the drug in the silicone elastomer [1,3,12]. For
example, Eqs. (1) and (2) model the release of drug
under sink conditions from matrix- and reservoir-type
IVRs, respectively, where Q is the release per unit area,
t is time, A is the drug loading per unit volume in a
matrix device, DSIL is the effective silicone diffusion
coefﬁcient of the drug, CSIL is the silicone solubility of
the drug, and h is the thickness of the sheath layer in a
reservoir device
Q ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
DSILð2A  CSILÞCSILt
p
; ð1Þ
Q ¼
DSILCSILt
h
: ð2Þ
These equations have been used to determine the
silicone diffusion coefﬁcient of certain steroidal drugs
for intravaginal administration [3,13]. Brieﬂy, a linear Q
versus Ot or t release proﬁles is plotted whose gradient is
a function of both DSIL and CSIL: Thus, if CSIL is
known, DSIL can be determined easily. However,
there are practical difﬁculties associated with directly
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measuring the solubility of a species in a polymeric
network. Unlike simple saturated solutions, it is
impossible to ﬁlter the excess material from a drug-
saturated polymer network. For this reason, approx-
imation techniques are commonly employed. For
example, the solubility of drugs in low molecular weight
silicone oils has been widely used as an approximation
to silicone elastomer solubility [3,13,14]. However, there
are inevitably some compromises associated with this
indirect approach to solubility determination. It is
common practice to incorporate various quantities of
ﬁnely ground ﬁllers, such as diatomaceous earth, into
silicone elastomers for IVR manufacture to improve
their mechanical properties. The presence of ﬁllers is
known to decrease the effective silicone diffusion
coefﬁcient of steroidal drugs in silicone matrices as a
result of the Langmuir adsorption of molecules onto the
ﬁller particles [15–17]. Also, drug solubility is expected
to depend on both the network chain length and the
degree of cross-linking. Clearly, these factors are not
taken into account in the silicone oil solubility
methodology.
In an attempt to overcome some of these compro-
mises, alternative direct methods for determination of
drug solubility in a silicone elastomer are required.
Theeuwes at al. described a now widely used differential
scanning calorimetry method for determining quantita-
tively the concentration of progesterone and cholesterol
at their melting point in polydimethylsiloxane rubber
[18]. Here we report a novel application of dynamic
mechanical analysis (DMA) in the determination of
silicone solubilities for a range of drugs and pharma-
ceutical excipients.
2. Experimental
2.1. Materials
Silicone elastomer base MED-6382, consisting of a
mixture of high (10,000Da) and low (2000Da) mole-
cular weight a,o-hydroxy terminated poly(dimethyl-
siloxanes), a reinforcement ﬁller (diatomaceous earth),
a low molecular weight polydimethylsiloxane processing
ﬂuid (to modify viscosity for injection molding pur-
poses), and tetrapropoxysilane (TPOS) were obtained
from Nusil Technology (Carpinteria, USA). Stannous 2-
ethyl-hexanoate (stannous octoate), 17b-estradiol (E2),
oleyl alcohol (OA) and norethisterone acetate (NetAc)
were purchased from Sigma (UK). Poly(ethyleneglycol)s
(PEG) 1000, 2000 and 6000 and poly(dimethylsiloxane)
200s ﬂuid were purchased from Aldrich (UK). Triclo-
san (TRIC) was purchased from CIBA Speciality
Chemicals plc and oxybutynin free-base (OXY) was
supplied by Orgamol (Evionnaz, Switzerland). All
materials were used as received.
2.2. Preparation of the silicone strips
A 2kg batch of the silicone elastomer mix was
prepared by thoroughly mixing 2.5 parts by weight of
TPOS with 100 parts of MED-6382 silicone elastomer
base in a Kenwood Major food mixer for 30min. Each
of the following drugs or pharmaceutical excipients
(polyethylene 6000, polyethylene glycol 2000, polyethy-
lene glycol 1000, oxybutynin, triclosan, oleyl alcohol,
norethisterone acetate, 17b-estradiol) was then hand-
blended into 35 g samples of the silicone elastomer mix
at various concentrations (1–20%, Table 1) to produce
the active elastomer mix, which was then allowed to
stand overnight to remove air entrapped during blend-
ing. One percent by weight of the curing catalyst,
stannous 2-ethyl-hexanoate, was then added dropwise to
the active silicone mixes and mixed for 30 s with a glass
rod before injecting the mixes via a disposable 60ml
concentric-tipped plastic syringe into a specially manu-
factured aluminum mold of dimensions 12.75
3.12 200mm. The dimensions of the mold were chosen
to match the sample constraints of the three-point bend
clamp of the dynamic mechanical analyzer. The mold
was placed in a pre-heated oven (801C) for 5min to
allow the active silicone mix to cure. These conditions
were selected to mimic a typical IVR manufacturing
process. The cured elastomer strip was then removed
from the mold, cut into sections approximately 30mm in
length and stored for 1 week at ambient conditions in
preparation for DMA analysis.
2.3. Dynamic mechanical characterization
DMA is a technique that is employed in the structural
analysis of viscoelastic materials, that is, materials
displaying both elastic and dissipative components of
deformation. The technique involves applying an
oscillatory strain wave to a sample which results in
an oscillatory stress response with a phase lag (d) in
between which is a measurement of the viscous
contribution. A DMA 2980 dynamic mechanical
Fig. 1. Matrix-type silicone intravaginal ring. Dimensions: 54mm
external diameter, 9mm cross-sectional diameter.
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analyzer (TA instruments, Leatherhead, UK) was used
to characterize the mechanical properties of the drug/
excipient-loaded silicone strips. The silicone elastomer
strips were mounted on a 3-point bend clamp, as
illustrated in Fig. 2, the distance between the ﬁxed
clamp support bars being 20.00mm. The sample was
then periodically deformed using a static force of
0.010n, an oscillatory amplitude of 200 mm, an oscilla-
tory frequency of 1Hz and an autotension of 150%. The
autotension is the percentage of the static force needed
to statically deform the sample by an amount equal to
the oscillation amplitude. After establishing a reprodu-
cible response at ambient temperature, the sample was
heated at 21/min over a broad temperature range
encompassing 371C and the melt temperature of the
drug/excipient. Three repetitions were made for each
strip. The parameters measured were storage modulus
(G0), loss modulus (G00) and tan d:
2.4. Solubility of excipients/drugs in low molecular
weight polydimethylsiloxane fluid
The silicone solubility of the ultraviolet-active drugs/
excipients (norethisterone acetate, estradiol and oxybu-
tynin) was determined in triplicate according to a
previously described UV-HPLC method [3]. Brieﬂy,
approximately 100mg of each drug was added to 3.0ml
of poly(dimethylsiloxane) 200s ﬂuid. After equilibra-
tion for 48 h at 371C in an orbital shaker (Model
10 400.XX2.C, Sanyo Gallenkamp, Uxbridge,UK;
60 rpm, 32mm orbit diameter) the saturated solutions
were ﬁltered at 371C (Nalgene cellulose acetate ﬁlters,
0.2 mm) and 1.0ml of the ﬁltrate extracted into 100ml
acetonitrile. Drug solubilities in silicone were then
determined by reverse phase HPLC. The Shimadzu
HPLC system consisted of a model SIL-10AXL auto
injector, a model SCL-10A system controller, a model
LC-10AT solvent delivery module, a model FCV-10AL
low pressure gradient ﬂow valve, a model GT-154
degassing unit, a model SPD-10A uv-vis detector and a
Table 1
Melting points and changes in storage modulus observed in the dynamic mechanical plots of storage modulus vs. temperature
Drug/excipient Mean7SD of observed
melting point (1C)
Change in storage modulus DG0 (MPa) (standard deviation, n ¼ 3)
% drug excipient concentration
1 2 5 7.5 10 15 20
PEG 6000 65.770.7 1.72 4.21 7.81
(0.27) (0.30)
(0.57)
PEG 2000 55.375.0 0.09 1.04 2.64 4.63
(0.02) (0.17) (0.12) (0.19)
PEG 1000 35.47 1.5 0.06 0.27 0.60 2.07
(0.02) (0.04) (0.05) (0.18)
Oxybutynin 59.0 71.0 a 0.10 1.68 3.20 6.58
(0.01) (0.23) (0.19)
(0.46)
Triclosan 62.272.1 a 0.61 1.84 5.08
(0.07) (0.45) (0.30)
Oleyl Alcohol 7.072.7 0.02 0.45 1.05 2.68b
(0.01) (0.09) (0.07) (0.16)
Norethisterone Acet. 153.572.8 a 1.21 3.53 8.04
(0.15) (0.40)
(0.42)
Estradiol 176.074.4 1.52 1.87 4.37 7.29
(0.10) (0.22) (0.35) (0.27)
aNo decrease in storage modulus observed for this sample.
b9.4% oleyl acohol.
Fig. 2. Three-point bend clamp loaded with silicone elastomeric strip.
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4.6mm i.d. 150mm Luna 5 mm C18 column (Phenom-
enex, Cheshire, UK). HPLC analysis was performed at
ambient temperature in isocratic mode, using an
acetonitrile/pH 5 acetate buffer mobile phase delivered
at 1.5ml/min and 10 ml injection volumes. Speciﬁc
parameters relating to each assay are: norethisterone
acetate—85/15 mobile phase, 220 nm detection wave-
length, 2.2min retention time; estradiol—50/50 mobile
phase, 281 nm detection wavelength, 2.0min retention
time; oxybutynin—45/55 mobile phase, 220 nm detec-
tion wavelength, 2.0min retention time. The silicone
solubilities of each drug were calculated using linear
calibration curves produced by plotting peak areas
versus concentration for a range of stock calibration
solutions prepared in acetonitrile.
3. Results and discussion
Dynamic mechanical analysis is a versatile technique
that may be used to simultaneously characterize both
the mechanical and thermal properties of a wide range
of polymeric materials of pharmaceutical and biomedi-
cal signiﬁcance [19]. To date, it has been used to measure
glass transition temperature, blend compatibility, me-
chanical moduli, damping properties and rates of
curing. In this study, a novel DMA method for
determination of the silicone elastomer solubility of a
range of drugs and pharmaceutical excipients at their
melting point is reported. The drugs chosen represent
examples of therapeutic agents currently being evaluated
for IVR development [1–4,8–10], while the choice of
excipients includes materials being investigated in our
laboratory for modifying drug release from the rings.
Representative plots of storage modulus vs. tempera-
ture are shown in Figs. 3 and 4 for NetAc and PEG
6000-loaded silicones, respectively. The other drug/
excipient-loaded silicone samples produced similar
plots. At higher drug/excipient loadings, G0 is observed
to decrease sharply at the drug/excipient melting point.
Table 1 provides a summary of the mean decrease in
storage moduli (DG0) at the melt temperature for those
samples in which it is observed. The coefﬁcient of
variation for the triplicate DG0 measures waso25% for
all samples, and typically o12%. Fig. 5 shows repre-
sentative plots of DG0 vs. drug/excipient concentration
for NetAc and PEG 6000-loaded silicones. Table 2
summarizes this information for all samples. The effect
of drug/excipient concentration on the storage modulus
at 371C is shown in Fig. 6.
In Figs. 3 and 4, the effects on G0 (a measure of the
‘stiffness’ of a material) of incorporating various
concentrations of norethisterone acetate and polyethy-
lene glycol 6000, respectively, are aptly demonstrated.
The blank silicone matrix shows an increase
(4.3–6.0MPa) in G0 over the temperature range. On
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incorporation of 1% NetAc into the silicone elastomer,
a similar trend when shifted to higher G0 values is
observed. The increase in G0 with increasing NetAc
concentration is also observed for the 5%, 10% and
20% NetAc samples. However, unlike the 1% sample, a
discontinuity is observed at approximately 1601C in
each plot, a temperature corresponding to the melt
temperature of NetAc. The discontinuity cannot be
attributed to any thermo-mechanical transitions of the
silicone elastomer, as evidenced by the linear modulus–
temperature plot for the blank silicones (Figs. 3 and 4).
The insensitivity of storage modulus to temperature has
been noted previously for silicone elastomeric denture
soft lining materials [20]. Poly(dimethylsiloxane)s typi-
cally display a glass transition, a crystallization transi-
tion and a melting transition at approximately 1201C,
901C and 401C, respectively [21].
The magnitude of the discontinuity, as represented by
the decrease in G0 (Table 1), is clearly linearly propor-
tional to the concentration of NetAc in the silicone
elastomer (Table 2 and Fig. 5). Thus, in the 1% NetAc
sample, all of the drug must be solubilized within the
silicone elastomer near the melt temperature, since no
melt-associated decrease in G0 of the silicone elastomer
is observed. At higher NetAc concentrations, a fraction
of the drug remains undissolved giving rise to a
concentration-dependent decrease in G0 on melting.
By plotting DG0 vs. NetAc concentration (Fig. 5), a
straight-line relationship is observed whose x-axis
intercept corresponds to the solubility of the drug in
the silicone elastomer at the melt temperature. Similar
linear, best-ﬁt plots are observed for the other drug/
excipient samples investigated (r2 > 0:96), producing
silicone elastomer solubilities of between 1.9 and
23mg/g. These values are comparable with those
obtained for cholesterol (35mg/g, melting point 1311C)
and progesterone (6mg/g, melting point 1291C) using a
related differential scanning calorimetry method [17].
Estradiol, whose exceptionally poor silicone solubility
has prevented the development of an IVR capable of
providing the clinically desired >50 mg/day release rate
required for estrogen replacement therapy [1–3], shows a
negative solubility value (1.21mg/g, Table 2) as
determined by the dynamic mechanical method. Such
a negative value demonstrates the difﬁculty in using this
technique for substances with very poor silicone
solubility.
It is important to realize that the solubilities measured
according to this dynamic mechanical method only
apply at the melting point of the substance under
investigation. Thus, for the high melting point drugs the
calculated solubility is typically several orders of
magnitude greater than the solubility determined in
silicone oil at 371C (Table 2). However, for the lower
melting oxybutynin the DMA solubility value of
15.6mg/g at 591C relates well to 10.7mg/g measured
at 371C in silicone oil.
In addition to the quantiﬁcation of silicone elastomer
solubilities, the results of the present study also
demonstrate the effect of drug/excipient concentrations
upon the mechanical properties of silicone devices. At
body temperature, the two liquid excipients, PEG 1000
and oleyl alcohol, do not show the increasing stiffness
(G0) associated with increasing concentration of the
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Fig. 6. Inﬂuence of drug/excipient concentration on the magnitude of
the storage modulus of silicone elastomer at 371C.
Table 2
Silicone elastomer and silicone oil solubilities of drugs and excipients
Drug/excipient Gradient of best ﬁt line R2 coefﬁcient X-axis intercept
(solubility at mp, mg/g)
Mean silicone oil
solubility7SD (mg/g)
PEG 6000 0.40 0.99 1.9 —
PEG 2000 0.49 0.98 1.9 —
PEG 1000 0.22 0.96 11 —
Oxybutynin 0.50 1.00 15.6 10.69670.833
Triclosan 0.57 0.99 12.5 —
Oleyl alcohol 0.31 0.99 9.3 —
Norethisterone acet. 0.46 1.00 23 0.62270.041
Estradiol 0.66 0.99 1.21 0.00470.001
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higher melting drugs/excipients (Fig. 6). In fact, increas-
ing the PEG 1000 concentration has little inﬂuence on
G0; while increasing oleyl alcohol concentration shows a
signiﬁcant decrease in G0:
4. Conclusions
A novel dynamic mechanical method for determining
the solubilities of drugs and pharmaceutical excipients in
silicone elastomeric drug delivery devices is reported.
The method has obvious advantages over other approx-
imation methods in that the solubility is measured
directly in the elastomer and thus includes effects
associated with molecular weight, cross-linking density
and the presence of ﬁller. The disadvantage is solubility
determination is measured at the drug/excipient melting
point, rather than at body temperature. However, for
drugs such as oxybutynin, similar values were obtained
using the dynamic mechanical method and the silicone
oil approximation method, suggesting that the dynamic
mechanical method is well suited to substances whose
melting point is close to body temperature.
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